In a pilot Phase II neoadjuvant trial testing Cetuximab combined with docetaxel, the pre-therapy ratio between CD8+ and FOXP3+ TILs was predictive of pathologic complete response, showing that the immune component of the tumor microenvironment may play an important role in predicting TNBC response to this neoadjuvant therapy [50]. Here, CD8A is linked to neoplasm.